Equity Overview
Price & Market Data
Price: $0.591
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $14,754,966
Volume: 0
Performance Metrics
1 Week: 6.29%
1 Month: -6.19%
3 Months: -19.56%
6 Months: -37.37%
1 Year: -79.62%
YTD: -19.05%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.